Zobrazeno 81 - 90
of 726
pro vyhledávání: '"Egbert F. Smit"'
Autor:
Sjoukje F Oosting, Astrid A M van der Veldt, Rudolf S N Fehrmann, Corine H GeurtsvanKessel, Rob S van Binnendijk, Anne-Marie C Dingemans, Egbert F Smit, T Jeroen N Hiltermann, Gerco den Hartog, Mathilda Jalving, Tatjana T Westphal, Arkajyoti Bhattacharya, Faye de Wilt, Annemarie Boerma, Lisanne van Zijl, Guus F Rimmelzwaan, Pia Kvistborg, Cecile A C M van Els, Nynke Y Rots, Debbie van Baarle, John B A G Haanen, Elisabeth G E de Vries
Publikováno v:
The Lancet Oncology, 23(7), 833-835. Lancet Publishing Group
Lancet Oncology, 23(7), 833-835. ELSEVIER SCIENCE INC
Oosting, S F, van der Veldt, A A M, Fehrmann, R S N, GeurtsvanKessel, C H, van Binnendijk, R S, Dingemans, A-M C, Smit, E F, Hiltermann, T J N, den Hartog, G, Jalving, M, Westphal, T T, Bhattacharya, A, de Wilt, F, Boerma, A, van Zijl, L, Rimmelzwaan, G F, Kvistborg, P, van Els, C A C M, Rots, N Y, van Baarle, D, Haanen, J B A G & de Vries, E G E 2022, ' Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours ', The Lancet Oncology, vol. 23, no. 7, pp. 833-835 . https://doi.org/10.1016/S1470-2045(22)00203-0
Lancet Oncology, 23(7), 833-835. ELSEVIER SCIENCE INC
Oosting, S F, van der Veldt, A A M, Fehrmann, R S N, GeurtsvanKessel, C H, van Binnendijk, R S, Dingemans, A-M C, Smit, E F, Hiltermann, T J N, den Hartog, G, Jalving, M, Westphal, T T, Bhattacharya, A, de Wilt, F, Boerma, A, van Zijl, L, Rimmelzwaan, G F, Kvistborg, P, van Els, C A C M, Rots, N Y, van Baarle, D, Haanen, J B A G & de Vries, E G E 2022, ' Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours ', The Lancet Oncology, vol. 23, no. 7, pp. 833-835 . https://doi.org/10.1016/S1470-2045(22)00203-0
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3faeb72ddc1ab94cc99e2975667c2840
https://research.vumc.nl/en/publications/ce00c378-f94b-45ef-b9a7-6ef58bfc57d2
https://research.vumc.nl/en/publications/ce00c378-f94b-45ef-b9a7-6ef58bfc57d2
Autor:
Remi Veillon, Hiroshi Sakai, Xiuning Le, Enriqueta Felip, Alexis B. Cortot, Egbert F. Smit, Keunchil Park, Frank Griesinger, Christian Britschgi, Yi-Long Wu, Barbara Melosky, Shobhit Baijal, Gilberto de Castro Jr, Michaela Sedova, Karin Berghoff, Gordon Otto, Paul K. Paik
Publikováno v:
Scientia
Edema; Nausea; Non-small cell lung cancer Edema; Náuseas; Cáncer de pulmón de células no pequeñas Edema; Nàusees; Càncer de pulmó de cèl·lules no petites Introduction The MET inhibitor tepotinib demonstrated durable clinical activity in pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8c491a32b262d254a14a8a193afbf3c
https://doi.org/10.5167/uzh-222025
https://doi.org/10.5167/uzh-222025
Autor:
Hendrik Koffijberg, Valesca P. Retèl, Michiel van de Ven, Wim H. van Harten, Egbert F. Smit, Kim Monkhorst, Maarten Joost IJzerman
Publikováno v:
Journal of Molecular Diagnostics, 23(4), 484-494. Elsevier Inc.
Journal of Molecular Diagnostics, 23(4), 484-494. Association of Molecular Pathology
The Journal of Molecular Diagnostics, 23(4), 484-494. ELSEVIER SCIENCE INC
Journal of Molecular Diagnostics, 23(4), 484-494. Association of Molecular Pathology
The Journal of Molecular Diagnostics, 23(4), 484-494. ELSEVIER SCIENCE INC
The continued introduction of biomarkers and innovative testing methods makes already complex diagnosis in patients with stage IV nonesmall-cell lung cancer (NSCLC) even more complex. This study primarily analyzed variations in biomarker testing in c
Autor:
M. Whipple Neibauer, Solange Peters, G. De Castro, Rachel E. Sanborn, M.C. Garassino, J. Mazieres, A. Stojadinovic, Vamsidhar Velcheti, Egbert F. Smit, E. Zhi, S.S. Ramalingam, David R. Spigel, Michael Thomas
Publikováno v:
Annals of Oncology. 32:S1030-S1032
Autor:
Adrianus J. de Langen, Danielle J. Vugts, Guus A.M.S. van Dongen, Berlinda J. de Wit–van der Veen, Otto S. Hoekstra, Egbert F. Smit, Frank Johannes Borm, Daniela E. Oprea-Lager, Erik Thunnissen, Ronald Boellaard, Anna-Larissa N. Niemeijer, Jasper Smit, Marc C. Huisman
Publikováno v:
Journal of Nuclear Medicine, 63(5), 686-693. Society of Nuclear Medicine Inc.
Smit, J, Borm, F J, Niemeijer, A-L N, Huisman, M C, Hoekstra, O S, Boellaard, R, Oprea-Lager, D E, Vugts, D J, van Dongen, G A M S, de Wit-van der Veen, B J, Thunnissen, E, Smit, E F & de Langen, A J 2022, ' PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer ', Journal of Nuclear Medicine, vol. 63, no. 5, pp. 686-693 . https://doi.org/10.2967/jnumed.121.262473
Journal of Nuclear Medicine, 63(5), 686-693. SOC NUCLEAR MEDICINE INC
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 63(5), 686-693
Smit, J, Borm, F J, Niemeijer, A-L N, Huisman, M C, Hoekstra, O S, Boellaard, R, Oprea-Lager, D E, Vugts, D J, van Dongen, G A M S, de Wit-van der Veen, B J, Thunnissen, E, Smit, E F & de Langen, A J 2022, ' PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer ', Journal of Nuclear Medicine, vol. 63, no. 5, pp. 686-693 . https://doi.org/10.2967/jnumed.121.262473
Journal of Nuclear Medicine, 63(5), 686-693. SOC NUCLEAR MEDICINE INC
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 63(5), 686-693
Background: Better biomarkers are needed to predict treatment outcome in NSCLC patients treated with anti PD-(L)1 checkpoint inhibitors. PD-L1 immunohistochemistry has limited predictive value, possibly due to tumor heterogeneity of PD-L1 expression.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c4edad85d4f4c7776c62955765b913c
https://research.vumc.nl/en/publications/66be6300-ca81-41b8-bdaa-5834514ee6c6
https://research.vumc.nl/en/publications/66be6300-ca81-41b8-bdaa-5834514ee6c6
Autor:
Vincent van der Noort, José Belderbos, Max Dahele, Pieter J M Joosten, Houke M. Klomp, Jan W.A. Oosterhuis, Judi N.A. van Diessen, Chris Dickhoff, Koen J. Hartemink, Maarten Smeekens, Kim Monkhorst, Rachel C. Numan, Michel M van den Heuvel, Egbert F. Smit
Publikováno v:
Joosten, P J M, Dickhoff, C, van der Noort, V, Smeekens, M, Numan, R C, Klomp, H M, van Diessen, J N A, Belderbos, J S A, Smit, E F, Monkhorst, K, Oosterhuis, J W A, van den Heuvel, M M, Dahele, M & Hartemink, K J 2022, ' Importance of tumour volume and histology in trimodality treatment of patients with Stage IIIA non-small cell lung cancer-results from a retrospective analysis ', Interactive Cardiovascular and Thoracic Surgery, vol. 34, no. 4, pp. 566-575 . https://doi.org/10.1093/icvts/ivab291
Interactive Cardiovascular and Thoracic Surgery, 34(4), 566-575. European Association for Cardio-Thoracic Surgery
Interactive Cardiovascular and Thoracic Surgery, 34, 566-575
Interactive Cardiovascular and Thoracic Surgery, 34, 4, pp. 566-575
Interactive Cardiovascular and Thoracic Surgery, 34(4), 566-575. European Association for Cardio-Thoracic Surgery
Interactive Cardiovascular and Thoracic Surgery, 34, 566-575
Interactive Cardiovascular and Thoracic Surgery, 34, 4, pp. 566-575
OBJECTIVES Chemoradiotherapy (CRT) has been the backbone of guideline-recommended treatment for Stage IIIA non-small cell lung cancer (NSCLC). However, in selected operable patients with a resectable tumour, good results have been achieved with trimo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8679f6d2ca1b2de5b5871c4de635c59
https://research.vumc.nl/en/publications/c45f00c5-8293-47e1-bcb9-84e22d366dd3
https://research.vumc.nl/en/publications/c45f00c5-8293-47e1-bcb9-84e22d366dd3
Autor:
Santiago Ponce Aix, Tudor Eliade Ciuleanu, Alejandro Navarro, Sophie Cousin, Laura Bonanno, Egbert F Smit, Alberto Chiappori, Maria Eugenia Olmedo, Ildiko Horvath, Christian Grohé, Anna F Farago, José Antonio López-Vilariño, Martin Cullell-Young, Antonio Nieto, Noelia Vasco, Javier Gómez, Carmen Kahatt, Ali Zeaiter, Enric Carcereny, Jaromir Roubec, Konstantinos Syrigos, Gregory Lo, Isidoro Barneto, Anthony Pope, Amparo Sánchez, Joseph Kattan, Konstantinos Zarogoulidis, Cornelius F Waller, Helge Bischoff, Oscar Juan-Vidal, Niels Reinmuth, Manuel Dómine, Luis Paz-Ares
Publikováno v:
The Lancet. Respiratory medicine. 11(1)
Lurbinectedin is a synthetic marine-derived anticancer agent that acts as a selective inhibitor of oncogenic transcription. Lurbinectedin monotherapy (3·2 mg/mIn this phase 3, open-label, randomised study, adult patients aged 18 years or older with
Autor:
René J, Boosman, Merel, Jebbink, Wouter B, Veldhuis, Stefanie L, Groenland, Bianca A M H, van Veggel, Pim, Moeskops, Adrianus J, de Langen, Jos H, Beijnen, Egbert F, Smit, Alwin D R, Huitema, Neeltje, Steeghs
Publikováno v:
Pharmaceutical research. 39(10)
Osimertinib, an irreversible inhibitor of the epidermal growth factor receptor (EGFR) is an important drug in the treatment of EGFR-mutation positive non-small cell lung cancer (NSCLC). Clinical trials with osimertinib could not demonstrate an exposu
Autor:
Otto S. Hoekstra, Egbert F. Smit, Guus A.M.S. van Dongen, Berlinda van de Veen, Adrianus J. de Langen, Idris Bahce, Marc C. Huisman, Danielle J. Vugts, Daniela E Oprea Lager, Anna-Larissa N. Niemeijer, Ronald Boellaard, Erik Thunnissen
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 63(3), 362-367
Niemeijer, A-L N, Oprea-Lager, D E, Huisman, M C, Hoekstra, O S, Boellaard, R, de Wit-van der Veen, B J, Bahce, I, Vugts, D J, van Dongen, G A M S, Thunnissen, E, Smit, E F & de Langen, A J 2022, ' Study of 89 Zr-Pembrolizumab PET/CT in Patients with Advanced-Stage Non-Small Cell Lung Cancer ', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, vol. 63, no. 3, pp. 362-367 . https://doi.org/10.2967/jnumed.121.261926, https://doi.org/10.2967/jnumed.121.261926
Niemeijer, A-L N, Oprea-Lager, D E, Huisman, M C, Hoekstra, O S, Boellaard, R, de Wit-van der Veen, B J, Bahce, I, Vugts, D J, van Dongen, G A M S, Thunnissen, E, Smit, E F & de Langen, A J 2022, ' Study of 89 Zr-Pembrolizumab PET/CT in Patients with Advanced-Stage Non-Small Cell Lung Cancer ', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, vol. 63, no. 3, pp. 362-367 . https://doi.org/10.2967/jnumed.121.261926, https://doi.org/10.2967/jnumed.121.261926
The tumor programmed death ligand 1 (PD-L1) proportion score is the current method for selecting non-small cell lung cancer (NSCLC) patients for single-agent treatment with pembrolizumab, a programmed cell death 1 (PD-1) monoclonal antibody. However,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7970527de6db97efc4e9880e2ecbf4d2
https://research.vumc.nl/en/publications/70b0c9bc-4154-4c9f-8dbc-74fde31746fd
https://research.vumc.nl/en/publications/70b0c9bc-4154-4c9f-8dbc-74fde31746fd
Autor:
Laurien J Zeverijn, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Anke A M G Pisters van Roy, Lonneke Timmers, T H Ly Tran, Jolanda E de Boer, Gijsbrecht F de Wit, Birgit S Geurts, Hans Gelderblom, Henk M W Verheul, Nicole Blijlevens, A N Machteld Wymenga, Ferry A L M Eskens, Egbert F Smit, Haiko J Bloemendal, Emile E Voest
Publikováno v:
Zeverijn, L J, van Waalwijk van Doorn-Khosrovani, S B, van Roy, A A M G P, Timmers, L, Ly Tran, T H, de Boer, J E, de Wit, G F, Geurts, B S, Gelderblom, H, Verheul, H M W, Blijlevens, N, Wymenga, A N M, Eskens, F A L M, Smit, E F, Bloemendal, H J & Voest, E E 2022, ' Harmonising patient-access programmes : the Dutch DRUG Access Protocol platform ', The Lancet Oncology, vol. 23, no. 2, pp. 198-201 . https://doi.org/10.1016/S1470-2045(21)00707-5
The Lancet Oncology, 23(2), 198-201. Lancet Publishing Group
Lancet Oncology, 23, 198-201
Lancet Oncology, 23, 2, pp. 198-201
The Lancet Oncology, 23(2), 198-201. Lancet Publishing Group
Lancet Oncology, 23, 198-201
Lancet Oncology, 23, 2, pp. 198-201
Item does not contain fulltext
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4e79f0dca3475d812d212a606ef4951
https://research.vumc.nl/en/publications/3b1be06b-d5da-4ce0-8d91-ec8744ecd5cb
https://research.vumc.nl/en/publications/3b1be06b-d5da-4ce0-8d91-ec8744ecd5cb